MorphoGene is an early stage Swiss company currently led by Professor Hubbell of the University of Chicago who has successfully founded and led other pharma startups in the past. MorphoGene specializes in re-engineering growth factors using a high affinity ECM binding domain to aid growth factor adherence to the ECM for better local wound retention and efficacy in the treatment of chronic wounds.